ArticleVirology journal2025
Molecular diagnosis of viral hepatitis in the WHO African region: progress toward 2030 elimination goals.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global, regional, and national burden of chronic hepatitis B, 1990-2021, and projections to 2030: An urgent call for action to achieve hepatitis B elimination goals by 2030.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The WHO African Region bears a disproportionately high burden of hepatitis B and C virus infections, yet molecular diagnostic capacity remains limited, impeding accurate detection, treatment monitoring, and surveillance. This Letter highlights the critical role of molecular diagnostics, including nucleic acid amplification tests, viral load quantification, and genotypic characterization, in achieving the United Nations' 2030 viral hepatitis elimination targets. I have discussed the infrastructural, financial, and logistical challenges constraining molecular testing in the region, and underscore emerging innovations such as point-of-care viral load assays and portable sequencing technologies. Prioritizing accessible molecular diagnostics and genomic surveillance within national hepatitis control programs is essential to bridge existing gaps and advance toward global elimination goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.